Teva Pharmaceutical Industries Ltd (TEVA) - Net Assets

Latest as of December 2025: ILA7.92 Billion ILA ≈ $21.22 Million USD

Based on the latest financial reports, Teva Pharmaceutical Industries Ltd (TEVA) has net assets worth ILA7.92 Billion ILA (≈ $21.22 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA40.76 Billion ≈ $109.27 Million USD) and total liabilities (ILA32.84 Billion ≈ $88.04 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Teva Pharmaceutical Industries Ltd (TEVA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets ILA7.92 Billion
% of Total Assets 19.42%
Annual Growth Rate 13.5%
5-Year Change -29.6%
10-Year Change -77.38%
Growth Volatility 27.66

Teva Pharmaceutical Industries Ltd - Net Assets Trend (1985–2025)

This chart illustrates how Teva Pharmaceutical Industries Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Teva Pharmaceutical Industries Ltd assets under control for the complete picture of this company's asset base.

Annual Net Assets for Teva Pharmaceutical Industries Ltd (1985–2025)

The table below shows the annual net assets of Teva Pharmaceutical Industries Ltd from 1985 to 2025. For live valuation and market cap data, see Teva Pharmaceutical Industries Ltd (TEVA) total market value.

Year Net Assets Change
2025-12-31 ILA7.92 Billion
≈ $21.22 Million		 +38.39%
2024-12-31 ILA5.72 Billion
≈ $15.34 Million		 -29.61%
2023-12-31 ILA8.13 Billion
≈ $21.79 Million		 -6.50%
2022-12-31 ILA8.69 Billion
≈ $23.30 Million		 -22.71%
2021-12-31 ILA11.24 Billion
≈ $30.14 Million		 +1.65%
2020-12-31 ILA11.06 Billion
≈ $29.65 Million		 -26.57%
2019-12-31 ILA15.06 Billion
≈ $40.38 Million		 -4.63%
2018-12-31 ILA15.79 Billion
≈ $42.34 Million		 -15.74%
2017-12-31 ILA18.75 Billion
≈ $50.25 Million		 -46.43%
2016-12-31 ILA34.99 Billion
≈ $93.82 Million		 +16.93%
2015-12-31 ILA29.93 Billion
≈ $80.23 Million		 +28.14%
2014-12-31 ILA23.36 Billion
≈ $62.61 Million		 +3.18%
2013-12-31 ILA22.64 Billion
≈ $60.69 Million		 -1.01%
2012-12-31 ILA22.87 Billion
≈ $61.31 Million		 +2.35%
2011-12-31 ILA22.34 Billion
≈ $59.90 Million		 +1.55%
2010-12-31 ILA22.00 Billion
≈ $58.99 Million		 +14.24%
2009-12-31 ILA19.26 Billion
≈ $51.63 Million		 +17.72%
2008-12-31 ILA16.36 Billion
≈ $43.86 Million		 +18.90%
2007-12-31 ILA13.76 Billion
≈ $36.89 Million		 +23.11%
2006-12-31 ILA11.18 Billion
≈ $29.97 Million		 +84.73%
2005-12-31 ILA6.05 Billion
≈ $16.22 Million		 +12.05%
2004-12-31 ILA5.40 Billion
≈ $14.48 Million		 +63.82%
2003-12-31 ILA3.30 Billion
≈ $8.84 Million		 +79.69%
2002-12-31 ILA1.83 Billion
≈ $4.92 Million		 +32.65%
2001-12-31 ILA1.38 Billion
≈ $3.71 Million		 +19.94%
2000-12-31 ILA1.15 Billion
≈ $3.09 Million		 +55.33%
1999-12-31 ILA742.30 Million
≈ $1.99 Million		 +12.54%
1998-12-31 ILA659.60 Million
≈ $1.77 Million		 +7.64%
1997-12-31 ILA612.80 Million
≈ $1.64 Million		 +14.50%
1996-12-31 ILA535.20 Million
≈ $1.43 Million		 +31.31%
1995-12-31 ILA407.60 Million
≈ $1.09 Million		 +19.04%
1994-12-31 ILA342.40 Million
≈ $917.96K		 +27.81%
1993-12-31 ILA267.90 Million
≈ $718.23K		 +20.08%
1992-12-31 ILA223.10 Million
≈ $598.12K		 +21.91%
1991-12-31 ILA183.00 Million
≈ $490.62K		 +34.96%
1990-12-31 ILA135.60 Million
≈ $363.54K		 +13.57%
1989-12-31 ILA119.40 Million
≈ $320.11K		 +20.48%
1988-12-31 ILA99.10 Million
≈ $265.68K		 +71.45%
1986-12-31 ILA57.80 Million
≈ $154.96K		 +15.83%
1985-12-31 ILA49.90 Million
≈ $133.78K		 --

Equity Component Analysis

This analysis shows how different components contribute to Teva Pharmaceutical Industries Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 58413.6% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock ILA58.00 Million 0.73%
Other Comprehensive Income ILA-2.39 Billion -30.22%
Other Components ILA24.01 Billion 303.43%
Total Equity ILA7.91 Billion 100.00%

Teva Pharmaceutical Industries Ltd Competitors by Market Cap

The table below lists competitors of Teva Pharmaceutical Industries Ltd ranked by their market capitalization.

Company Market Cap
Mirae Asset Venture Investment Co. Ltd
KQ:100790
 $1.09 Billion
Generation Development Group Ltd
AU:GDG
 $1.09 Billion
OceanFirst Financial Corp
NASDAQ:OCFC
 $1.09 Billion
Tiangong International Company Limited
F:34T1
 $1.09 Billion
Sivers IMA Holding AB
ST:SIVE
 $1.09 Billion
Guizhou Gas Group Corporation Ltd Class A
SHG:600903
 $1.09 Billion
Hangzhou Sunrise Technology Co Ltd
SHE:300360
 $1.09 Billion
Ningbo Dechang Electrical Machinery Made Co Ltd
SHG:605555
 $1.09 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Teva Pharmaceutical Industries Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 5,373,000,000 to 7,911,642,000, a change of 2,538,642,000 (47.2%).
  • Net income of 1,527,366,000 contributed positively to equity growth.
  • Other comprehensive income increased equity by 757,000,000.
  • Other factors increased equity by 254,276,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income ILA1.53 Billion +19.31%
Other Comprehensive Income ILA757.00 Million +9.57%
Other Changes ILA254.28 Million +3.21%
Total Change ILA- 47.25%

Book Value vs Market Value Analysis

This analysis compares Teva Pharmaceutical Industries Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1525.85x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 90884.70x to 1525.85x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1985-12-31 ILA0.11 ILA10380.00 x
1986-12-31 ILA0.13 ILA10380.00 x
1988-12-31 ILA0.29 ILA10380.00 x
1989-12-31 ILA0.35 ILA10380.00 x
1990-12-31 ILA0.34 ILA10380.00 x
1991-12-31 ILA0.44 ILA10380.00 x
1992-12-31 ILA0.54 ILA10380.00 x
1993-12-31 ILA0.63 ILA10380.00 x
1994-12-31 ILA0.71 ILA10380.00 x
1995-12-31 ILA0.83 ILA10380.00 x
1996-12-31 ILA1.09 ILA10380.00 x
1997-12-31 ILA1.25 ILA10380.00 x
1998-12-31 ILA1.35 ILA10380.00 x
1999-12-31 ILA1.51 ILA10380.00 x
2000-12-31 ILA2.21 ILA10380.00 x
2001-12-31 ILA2.53 ILA10380.00 x
2002-12-31 ILA3.26 ILA10380.00 x
2003-12-31 ILA5.58 ILA10380.00 x
2004-12-31 ILA7.83 ILA10380.00 x
2005-12-31 ILA8.87 ILA10380.00 x
2006-12-31 ILA13.84 ILA10380.00 x
2007-12-31 ILA16.53 ILA10380.00 x
2008-12-31 ILA19.88 ILA10380.00 x
2009-12-31 ILA21.45 ILA10380.00 x
2010-12-31 ILA23.83 ILA10380.00 x
2011-12-31 ILA24.85 ILA10380.00 x
2012-12-31 ILA26.08 ILA10380.00 x
2013-12-31 ILA26.55 ILA10380.00 x
2014-12-31 ILA27.17 ILA10380.00 x
2015-12-31 ILA34.45 ILA10380.00 x
2016-12-31 ILA34.69 ILA10380.00 x
2017-12-31 ILA17.09 ILA10380.00 x
2018-12-31 ILA14.40 ILA10380.00 x
2019-12-31 ILA12.81 ILA10380.00 x
2020-12-31 ILA9.16 ILA10380.00 x
2021-12-31 ILA9.28 ILA10380.00 x
2022-12-31 ILA7.11 ILA10380.00 x
2023-12-31 ILA6.71 ILA10380.00 x
2024-12-31 ILA4.75 ILA10380.00 x
2025-12-31 ILA6.80 ILA10380.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Teva Pharmaceutical Industries Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 19.31%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 8.18%
  • • Asset Turnover: 0.46x
  • • Equity Multiplier: 5.15x
  • Recent ROE (19.31%) is above the historical average (5.61%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1985 15.23% 8.33% 0.66x 2.79x ILA2.61 Million
1986 25.61% 10.60% 0.98x 2.47x ILA9.02 Million
1988 12.11% 5.68% 0.85x 2.50x ILA2.09 Million
1989 14.15% 6.01% 0.98x 2.40x ILA4.96 Million
1990 15.34% 6.32% 0.96x 2.54x ILA7.24 Million
1991 12.99% 7.25% 0.87x 2.07x ILA5.46 Million
1992 14.66% 8.02% 0.91x 2.00x ILA10.37 Million
1993 21.50% 11.45% 0.89x 2.10x ILA30.75 Million
1994 20.94% 12.18% 0.87x 1.98x ILA37.40 Million
1995 19.81% 11.95% 0.77x 2.16x ILA39.51 Million
1996 13.74% 7.70% 0.77x 2.32x ILA19.98 Million
1997 16.58% 9.09% 0.94x 1.94x ILA40.30 Million
1998 10.44% 6.17% 0.78x 2.18x ILA2.92 Million
1999 15.87% 9.19% 0.75x 2.31x ILA43.60 Million
2000 12.89% 8.48% 0.61x 2.48x ILA33.28 Million
2001 20.15% 13.39% 0.60x 2.51x ILA140.14 Million
2002 22.43% 16.29% 0.54x 2.53x ILA227.36 Million
2003 21.01% 21.09% 0.55x 1.80x ILA362.06 Million
2004 6.16% 6.91% 0.50x 1.79x ILA-207.09 Million
2005 17.75% 20.42% 0.51x 1.72x ILA468.07 Million
2006 4.90% 6.49% 0.41x 1.84x ILA-568.20 Million
2007 14.22% 20.75% 0.40x 1.71x ILA579.60 Million
2008 3.90% 5.73% 0.34x 2.02x ILA-995.00 Million
2009 10.40% 14.39% 0.41x 1.76x ILA77.80 Million
2010 15.18% 20.66% 0.41x 1.78x ILA1.14 Billion
2011 12.43% 15.07% 0.37x 2.26x ILA539.50 Million
2012 8.62% 9.66% 0.40x 2.22x ILA-313.80 Million
2013 5.62% 6.25% 0.43x 2.11x ILA-987.50 Million
2014 13.10% 15.07% 0.44x 1.99x ILA723.70 Million
2015 5.33% 8.08% 0.36x 1.82x ILA-1.39 Billion
2016 0.99% 1.50% 0.24x 2.79x ILA-3.00 Billion
2017 -93.70% -72.66% 0.32x 4.07x ILA-18.00 Billion
2018 -14.62% -11.40% 0.31x 4.13x ILA-3.62 Billion
2019 -7.15% -5.92% 0.29x 4.11x ILA-2.40 Billion
2020 -39.80% -23.95% 0.33x 5.05x ILA-4.99 Billion
2021 4.06% 2.63% 0.33x 4.64x ILA-610.80 Million
2022 -29.80% -15.77% 0.34x 5.57x ILA-3.14 Billion
2023 -7.45% -3.53% 0.36x 5.79x ILA-1.31 Billion
2024 -30.50% -9.91% 0.42x 7.32x ILA-2.18 Billion
2025 19.31% 8.18% 0.46x 5.15x ILA736.20 Million

Industry Comparison

This section compares Teva Pharmaceutical Industries Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $574,320,144
  • Average return on equity (ROE) among peers: 20.69%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Teva Pharmaceutical Industries Ltd (TEVA) ILA7.92 Billion 15.23% 4.15x $1.09 Billion
Canzon Israel Ltd (CNZN) $4.23 Million -112.18% 0.24x $1.81 Million
Intercure (INCR) $397.67 Million -17.05% 0.92x $36.39 Million
Intelicanna Ltd (INTL) $4.41 Billion 12.46% 8.24x $10.11 Million
Kamada (KMDA) $28.39 Million 0.92% 2.14x $371.30 Million
Nextage Therapeutics Ltd (NXTG) $3.66 Million -57.11% 0.64x $5.79 Million
Rekah Pharmaceutical Industry Ltd (REKA) $144.62 Million -15.54% 1.04x $35.99 Million
Seach Medical Group Ltd (SEMG) $31.38 Million 9.42% 0.14x $22.18 Million
Together Startup Network Ltd (TGTR) $549.00K 387.98% 0.54x $9.92 Million
Tikun Olam Cannbit Pharmaceuticals Ltd (TKUN) $143.82 Million -22.70% 0.32x $28.21 Million

About Teva Pharmaceutical Industries Ltd

TA:TEVA Israel Drug Manufacturers - Specialty & Generic
Market Cap
$32.40 Billion
ILA12.09 Trillion ILA
Market Cap Rank
#8743 Global
#86 in Israel
Share Price
ILA10380.00
Change (1 day)
+0.97%
52-Week Range
ILA5374.00 - ILA11350.00
All Time High
ILA25447.60
Categories
Companies in Israel Drug Manufacturers - Specialty & Generic
About

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more